Journal of Multidisciplinary Applied Natural Science
##plugins.themes.gdThemes.journalSlogan##
Scopus CiteScore 2024
4.8
Calculated on 05 May, 2025
SJR 2024
0.31
Powered by scimagojr.com
##plugins.themes.gdThemes.journalSlogan##
4.8
Calculated on 05 May, 2025
0.31
Powered by scimagojr.com
https://doi.org/10.47352/jmans.2774-3047.375
Dadan Ridwanuloh
Ade Danova
Elvira Hermawati
Warinthorn Chavasiri
Ihsanawati Ihsanawati
Anita Alni
Acetylcholinesterase (AChE) inhibition remains a central therapeutic approach for Alzheimer’s disease (AD), as it helps preserve synaptic acetylcholine levels, enhances cholinergic neurotransmission, and mitigates early cognitive decline. In this study, eight novel pyrrole–chalcone hybrids (3–10), consisting of four pyrrole–chalcones (3–6) and four pyrrole–chalcone amides (7–10), were designed, synthesized, and biologically evaluated for AChE inhibition. Among them, compound 8 (N-(4-methoxybenzyl)-pyrrole–chalcone amide) and compound 10 (N-(3,4-dimethoxybenzyl)-pyrrole–chalcone amide) demonstrated the strongest inhibitory activity, with IC₅₀ values of 3.1 and 2.8 µM, respectively, comparable to galantamine. Kinetic assays confirmed that both compounds act as noncompetitive inhibitors, as indicated by reduced Vmax without significant alteration in Km, while compound 10 exhibited Ki of 0.8 µM, reflecting high enzyme affinity. Molecular docking revealed strong binding interactions of compounds 8 and 10 with key AChE residues (Trp84, Phe330, Tyr334), supported by π–π stacking, π–alkyl interactions, and hydrogen bonding, with binding energies of –9.2 (compound 8) and –8.9 kcal/mol (compound 10). Molecular dynamics simulations further demonstrated that compound 10 forms a more stable and compact complex with AChE, as indicated by consistent RMSD values and a stable radius of gyration. SwissADME analysis confirmed favorable pharmacokinetic profiles for both ligands, including Lipinski compliance, high GI absorption, and absence of PAINS alerts, despite the lack of predicted BBB permeability. Overall, compound 10 emerges as the most promising noncompetitive AChE inhibitor in this series, exhibiting strong binding affinity, structural stability, and drug-likeness, thus warranting further optimization and in vivo evaluation.
[1] P. Mishra, A. Kumar, and G. Panda. (2019). "Anti-Cholinesterase Hybrids As Multi-Target-Directed Ligands Against Alzheimer's Disease (1998–2018)". Bioorganic & Medicinal Chemistry. 27 (6): 895-930. 10.1016/j.bmc.2019.01.025.
DOI: https://doi.org/10.1016/j.bmc.2019.01.025[2] A. Nandi, N. Counts, J. Bröker, S. Malik, S. Chen, R. Han, J. Klusty, B. Seligman, D. Tortorice, D. Vigo, and D. E. Bloom. (2024). "Cost Of Care For Alzheimer's Disease And Related Dementias In The United States: 2016 To 2060". npj Aging. 10 (1): 1-8. 10.1038/s41514-024-00136-6.
DOI: https://doi.org/10.1038/s41514-024-00136-6[3] P. T. Francis, A. M. Palmer, M. Snape, and G. K. Wilcock. (1999). "The Cholinergic Hypothesis Of Alzheimer's Disease: A Review Of Progress". Journal of Neurology, Neurosurgery & Psychiatry. 66 (2): 137-147. 10.1136/jnnp.66.2.137.
DOI: https://doi.org/10.1136/jnnp.66.2.137[4] R. T. Bartus, R. L. Dean, B. Beer, and A. S. Lippa. (1982). "The Cholinergic Hypothesis Of Geriatric Memory Dysfunction". Science. 217 (4558): 408-417. 10.1126/science.7046051.
DOI: https://doi.org/10.1126/science.7046051[5] H. Tago, T. Maeda, P. L. McGeer, and H. Kimura. (1992). "Butyrylcholinesterase-Rich Neurons In Rat Brain Demonstrated By A Sensitive Histochemical Method". Journal of Comparative Neurology. 325 (2): 301-312. 10.1002/cne.903250212.
DOI: https://doi.org/10.1002/cne.903250212[6] C. Ballard, N. Greig, A. Guillozet-Bongaarts, A. Enz, and S. Darvesh. (2005). "Cholinesterases: Roles In The Brain During Health And Disease". Current Alzheimer Research. 2 (3): 307-318. 10.2174/1567205054367838.
DOI: https://doi.org/10.2174/1567205054367838[7] A. H. Hasan, S. Shakya, F. H. Hussain, S. Murugesan, S. Chander, M. R. F. Pratama, S. Jamil, B. Das, S. Biswas, and J. Jamalis. (2023). "Design, Synthesis, Anti-Acetylcholinesterase Evaluation And Molecular Modelling Studies Of Novel Coumarin-Chalcone Hybrids". Journal of Biomolecular Structure and Dynamics. 41 (21): 11450-11462. 10.1080/07391102.2022.2162583.
DOI: https://doi.org/10.1080/07391102.2022.2162583[8] T. V. Sreevidya, B. Narayana, and H. S. Yathirajan. (2010). "Synthesis And Characterization Of Some Chalcones And Their Cyclohexenone Derivatives". Central European Journal of Chemistry. 8 (1): 174-181. 10.2478/s11532-009-0124-x.
DOI: https://doi.org/10.2478/s11532-009-0124-x[9] S. Liang, C. Chen, R. Chen, R. Li, W. Chen, G. Jiang, and L. Du. (2022). "Michael Acceptor Molecules In Natural Products And Their Mechanism Of Action". Frontiers in Pharmacology. 13 : 1033003. 10.3389/fphar.2022.1033003.
DOI: https://doi.org/10.3389/fphar.2022.1033003[10] Y. M. Lin, Y. Zhou, M. T. Flavin, L. M. Zhou, W. Nie, and F. C. Chen. (2002). "Chalcones And Flavonoids As Anti-Tuberculosis Agents". Bioorganic & Medicinal Chemistry. 10 (8): 2795-2802. 10.1016/S0968-0896(02)00094-9.
DOI: https://doi.org/10.1016/S0968-0896(02)00094-9[11] G. George, V. P. Koyiparambath, S. Sukumaran, A. S. Nair, L. K. Pappachan, A. G. Al-Sehemi, H. Kim, and B. Mathew. (2022). "Structural Modifications On Chalcone Framework For Developing New Class Of Cholinesterase Inhibitors". International Journal of Molecular Sciences. 23 (6): 3121. 10.3390/ijms23063121.
DOI: https://doi.org/10.3390/ijms23063121[12] Y. A. Malik, T. A. Awad, M. Abdalla, S. Yagi, H. A. Alhazmi, W. Ahsan, M. Albratty, A. Najmi, S. Muhammad, and A. Khalid. (2022). "Chalcone Scaffolds Exhibiting Acetylcholinesterase Enzyme Inhibition: Mechanistic And Computational Investigations". Molecules. 27 (10): 3181. 10.3390/molecules27103181.
DOI: https://doi.org/10.3390/molecules27103181[13] S. Khan, T. Iqbal, M. B. Khan, R. Hussain, Y. Khan, and H. W. Darwish. (2024). "Novel Pyrrole Based Triazole Moiety As Therapeutic Hybrid: Synthesis, Characterization And Anti-Alzheimer Potential With Molecular Mechanism Of Protein Ligand Profile". BMC Chemistry. 18 (1). 10.1186/s13065-024-01340-x.
DOI: https://doi.org/10.1186/s13065-024-01340-x[14] S. Sun, T. Shi, Y. Peng, H. Zhang, L. Zhuo, X. Peng, Q. Li, M. Wang, S. Wang, and Z. Wang. (2022). "Discovery Of Pyrrole Derivatives As Acetylcholinesterase-Sparing Butyrylcholinesterase Inhibitor". Frontiers in Pharmacology. 13 : 1043397. 10.3389/fphar.2022.1043397.
DOI: https://doi.org/10.3389/fphar.2022.1043397[15] V. Bhardwaj, D. Gumber, V. Abbot, S. Dhiman, and P. Sharma. (2015). "Pyrrole: A Resourceful Small Molecule In Key Medicinal Hetero-Aromatics". RSC Advances. 5 (20): 15233-15266. 10.1039/C4RA15710A.
DOI: https://doi.org/10.1039/C4RA15710A[16] A. Özdemir, M. D. Altıntop, B. Sever, H. K. Gençer, H. A. Kapkaç, Ö. Atlı, and M. Baysal. (2017). "A New Series Of Pyrrole-Based Chalcones: Synthesis And Evaluation Of Antimicrobial Activity, Cytotoxicity, And Genotoxicity". Molecules. 22 (12): 1-16. 10.3390/molecules22122112.
DOI: https://doi.org/10.3390/molecules22122112[17] A. Danova, A. C. Christy, I. Musthapa, F. Kurniadewi, W. Chavasiri, D. Mujahidin, R. Roswanda, and E. Hermawati. (2025). "Discovery Of New Acetylcholinesterase Inhibitors Derived From Quinazolinones: Synthesis, In Vitro, And Molecular Docking Study". Pharmacia. 72 : 1-10. 10.3897/pharmacia.72.e162676.
DOI: https://doi.org/10.3897/pharmacia.72.e162676.figure1[18] T. A. Halgren. (1996). "Merck Molecular Force Field. I. Basis, Form, Scope, Parameterization, And Performance Of MMFF94". Journal of Computational Chemistry. 17 (5-6): 490-519. 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P.
[19] H. Mirzaei, S. Zarbafian, E. Villar, S. Mottarella, D. Beglov, S. Vajda, I. C. Paschalidis, P. Vakili, and D. Kozakov. (2015). "Energy Minimization On Manifolds For Docking Flexible Molecules". Journal of Chemical Theory and Computation. 11 (3): 1063-1076. 10.1021/ct500155t.
DOI: https://doi.org/10.1021/ct500155t[20] S. Forli, R. Huey, M. E. Pique, M. F. Sanner, D. S. Goodsell, and A. J. Olson. (2016). "Computational Protein-Ligand Docking And Virtual Drug Screening With The AutoDock Suite". Nature Protocols. 11 (5): 905-919. 10.1038/nprot.2016.051.
DOI: https://doi.org/10.1038/nprot.2016.051[21] M. Naufal, E. Hermawati, A. Danova, I. W. Hidayat, and J. Al-Anshori. (2025). "Design, Synthesis, Bioevaluation, And Bioinformatics Study Of 5-Benzylidene Hydantoin Derivatives As Novel Tyrosine Kinase Inhibitors". ChemistryOpen. 2500158. 10.1002/open.202500158.
DOI: https://doi.org/10.1002/open.202500158[22] E. Krieger and G. Vriend. (2015). "New Ways To Boost Molecular Dynamics Simulations". Journal of Computational Chemistry. 36 (13): 996-1007. 10.1002/jcc.23899.
DOI: https://doi.org/10.1002/jcc.23899[23] Y. Duan, C. Wu, S. Chowdhury, M. C. Lee, G. Xiong, W. Zhang, R. Yang, P. Cieplak, R. Luo, T. Lee, J. Caldwell, J. Wang, and P. Kollman. (2003). "A Point-Charge Force Field For Molecular Mechanics Simulations Of Proteins Based On Condensed-Phase Quantum Mechanical Calculations". Journal of Computational Chemistry. 24 (16): 1999-2012. 10.1002/jcc.10349.
DOI: https://doi.org/10.1002/jcc.10349[24] L. Kang, X. Gao, H. Liu, X. Men, H. Wu, P. Cui, E. Oldfield, and J. Yan. (2018). "Structure-Activity Relationship Investigation Of Coumarin-Chalcone Hybrids With Diverse Side-Chains As Acetylcholinesterase And Butyrylcholinesterase Inhibitors". Molecular Diversity. 22 (4): 893-906. 10.1007/s11030-018-9839-y.
DOI: https://doi.org/10.1007/s11030-018-9839-y[25] P. Sawasdee, C. Sabphon, D. Sitthiwongwanit, and U. Kokpol. (2009). "Anticholinesterase Activity Of 7-Methoxyflavones Isolated From Kaempferia Parviflora". Phytotherapy Research. 23 (12): 1792-1794. 10.1002/ptr.2858.
DOI: https://doi.org/10.1002/ptr.2858[26] A. Sobha, A. Ganapathy, S. Mohan, N. Madhusoodanan, A. D. Babysulochana, K. Alaganandan, and S. B. Somappa. (2024). "Novel Small Molecule-Based Acetylcholinesterase (AChE) Inhibitors: From Biological Perspective To Recent Developments". European Journal of Medicinal Chemistry Reports. 12 : 100237. 10.1016/j.ejmcr.2024.100237.
DOI: https://doi.org/10.1016/j.ejmcr.2024.100237[27] R. Ramadhan and P. Phuwapraisirisan. (2015). "New Arylalkanones From Horsfieldia Macrobotrys, Effective Antidiabetic Agents Concomitantly Inhibiting α-Glucosidase And Free Radicals". Bioorganic & Medicinal Chemistry Letters. 25 (20): 4529-4533. 10.1016/j.bmcl.2015.08.069.
DOI: https://doi.org/10.1016/j.bmcl.2015.08.069[28] A. Danova, K. Pattanapanyasat, K. Hengphasatporn, Y. Shigeta, T. Rungrotmongkol, E. Hermawati, and W. Chavasiri. (2024). "Unlocking E-Arylidene Steroid Derivatives As Promising α-Glucosidase Inhibitors". ChemistrySelect. 9 (9): e202303887. 10.1002/slct.202303887.
DOI: https://doi.org/10.1002/slct.202303887[29] G. Kryger, I. Silman, and J. L. Sussman. (1999). "Structure Of Acetylcholinesterase Complexed With E2020 (Aricept): Implications For The Design Of New Anti-Alzheimer Drugs". Structure. 7 (3): 297-307. 10.1016/S0969-2126(99)80040-9.
DOI: https://doi.org/10.1016/S0969-2126(99)80040-9[30] A. M. Bondžić, T. D. Lazarević-Pašti, A. R. Leskovac, S. Ž. Petrović, M. B. Čolović, T. N. Parac-Vogt, and G. V. Janjić. (2020). "A New Acetylcholinesterase Allosteric Site Responsible For Binding Voluminous Negatively Charged Molecules—The Role In The Mechanism Of AChE Inhibition". European Journal of Pharmaceutical Sciences. 151 : 105376. 10.1016/j.ejps.2020.105376.
DOI: https://doi.org/10.1016/j.ejps.2020.105376[31] B. Kuzu, M. A. Alagoz, Y. Demir, I. Gulcin, S. Burmaoglu, and O. Algul. (2024). "Structure-Based Inhibition Of Acetylcholinesterase And Butyrylcholinesterase With 2-Aryl-6-Carboxamide Benzoxazole Derivatives: Synthesis, Enzymatic Assay, And In Silico Studies". Molecular Diversity. 671-693. 10.1007/s11030-024-10828-6.
DOI: https://doi.org/10.1007/s11030-024-10828-6[32] W. M. Pardridge. (2009). "Alzheimer's Disease Drug Development And The Problem Of The Blood-Brain Barrier". Alzheimer's & Dementia. 5 (5): 427-432. 10.1016/j.jalz.2009.06.003.
DOI: https://doi.org/10.1016/j.jalz.2009.06.003